Globus Medical (GMED) Pulls Back On Undervalued Calls, Is Fair Value Still $103?
Globus Medical (GMED) has drawn fresh attention after recent trading left the share price at $73.96. The stock has moved lower over the past month and the past three months, prompting closer scrutiny from investors.
Recent trading has come after a tougher stretch for Globus Medical, with the share price down 12.0% over the past month and 12.6% over the last quarter, even as the 1 year total shareholder return of 33.7% signals earlier momentum that has cooled.
Compare Globus Medical's recent pullback with other potential opportunities by scanning our hand picked list of 30 high quality undervalued stocks that combine quality fundamentals with compressed valuations.
Bulls see Globus Medical’s pullback as mispricing a growing musculoskeletal platform, while bears argue the earlier 1 year surge already captured that story. Which case do the current valuation markers support next?
Most Popular Narrative: 28% Undervalued
Globus Medical's most followed narrative sets fair value at $103.23 per share, well above the recent $73.96 close. This frames the current pullback as pricing in less than that thesis suggests.
The main thing that has to go right is continued execution on margin expansion from manufacturing efficiencies and M&A synergies, while keeping growth on track in robotics, trauma, international spine and neuromodulation despite volatility in Enabling Technologies and Nevro revenue.
The current valuation implies investors are not fully crediting the combination of mid 30s adjusted EBITDA margins, progress toward low 70s adjusted gross margins, EPS guidance upgrades and ongoing share repurchases in the Globus Medical share price.
See why 20 investors see Globus Medical as 28% undervalued.
Result: Fair Value of $103.23 (UNDERVALUED)
Still, the Globus Medical story can break if Excelsius system sales remain soft under lease heavy models, or if Nevro weakness drags on margins longer than expected.
Find out about the key risks to this Globus Medical narrative.
Next Steps
Sentiment around Globus Medical is split, which is exactly when fresh eyes can matter most. Move quickly, review the underlying data, and then see how the 5 key rewards.
Looking for more Globus Medical sized ideas?
If Globus Medical has you thinking harder about risk, reward, and timing, do not stop at one ticker. Use the Simply Wall Street Screener to surface fresh, data driven ideas before they move.
- Target potential mispricings by scanning a curated 30 high quality undervalued stocks that combine solid fundamentals with compressed valuations.
- Prioritize resilience by filtering for companies in a 31 resilient stocks with low risk scores that score well on financial strength and volatility metrics.
- Hunt for lesser known opportunities using a focused 16 high quality undiscovered gems where quality metrics stack up despite limited market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com